A-ju Science, Co., Ltd
- Biotech or pharma, therapeutic R&D
A-ju Science is developing novel therapeutic candidates directly targeting mutant mitochondrial DNA (mtDNA) for the treatment of mitochondria-related diseases, such as MELAS, a life-threatning orphan disease. Our proprietary technology selectively eliminating mutant mtDNA, leading to both a reduction in the number of dysfunctional mitochondria and an increase in the total mitochondrial population. This dual effect restores mitochondrial function at both the cellular and systemic levels.
Our lead program, CCC-018-TPP, is being developed as a potential curative treatment for mitochondrial diseases. The second candidate CCCh-560-TPP targets metastatic pan-cancer by inducing mitophagy-mediated clearance of mutant mitochondria, resulting in cancer cell death and normalization of the tumor microenvironment.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}